Integration of the Tumor Mutational Burden and Tumor Heterogeneity Identify an Immunological Subtype of Melanoma With Favorable Survival

The tumor mutational burden (TMB) has been reported as a predictive marker of the response to immune checkpoint inhibition (ICI) therapy in previous melanoma clinical trials. However, the TMB alone is not sufficient to accurately predict immunotherapy benefit. Additional biomarkers are needed for be...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Yanmei, Yang, Chunhe, He, Ning, Zhao, Guodong, Wang, Jianfei, Yang, Yadong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7661856/
https://www.ncbi.nlm.nih.gov/pubmed/33194669
http://dx.doi.org/10.3389/fonc.2020.571545

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7661856/
https://www.ncbi.nlm.nih.gov/pubmed/33194669
http://dx.doi.org/10.3389/fonc.2020.571545

Ejemplares similares